Protocol Ledger

NCT07717268 · Phase II · RECRUITING

Fractionated Stereotactic Radiotherapy Plus Second-generation Antiandrogen for Oligometastatic Castration-resistant Prostate Cancer Patients.

Interventional Phase II clinical trial protocol NCT07717268 sponsored by Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-05-16 Enrollment: 51 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07717268
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)51 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07717268
Protocol FieldVerified Registry Value
NCT IdentifierNCT07717268
Consolidated Lead SponsorInstituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment51 participants (ESTIMATED)
Registered Start Date2024-05-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07717268
Hospital Research SiteLocationSite Profile
Hospital Universitario Miguel ServetZaragoza, SpainOpen Hospital Dossier ->
Hospital Clinic de BarcelonaBarcelona, SpainOpen Hospital Dossier ->
Hospital Universitario de SalamancaSalamanca, SpainOpen Hospital Dossier ->
Hospital de La Santa Creu I Sant PauBarcelona, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI